Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy

@article{ONeill2015DevelopmentAE,
  title={Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy},
  author={Daniel O’Neill and D. Jones and M. Wade and James Grey and S. Nakjang and Wenrui Guo and D. Cork and B. Davies and S. Wedge and C. Robson and L. Gaughan},
  journal={Oncotarget},
  year={2015},
  volume={6},
  pages={26029 - 26040}
}
The persistence of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the unmet clinical need for the development of more effective AR targeting therapies. A key mechanism of therapy-resistance is by selection of AR mutations that convert anti-androgens to agonists enabling the retention of androgenic signalling in CRPC. To improve our understanding of these receptors in advanced disease we developed a physiologically-relevant model to analyse the global… Expand
BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients
Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
...
1
2
...

References

SHOWING 1-10 OF 48 REFERENCES
ARN-509: a novel antiandrogen for prostate cancer treatment.
Constitutive activity of the androgen receptor.
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).
Targeting the androgen receptor pathway in prostate cancer.
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
...
1
2
3
4
5
...